COVID-19 Trend Insights - Compiled on 6/11/2021
0 likes96 views
As of June 11, 2021, global COVID-19 cases reached 174.5 million, with a notable increase in South America, particularly in Argentina and Uruguay, while the U.S. experienced a mild increase in cases and deaths. The vaccine administration data indicates a diverse patient demographic, with 88% of vaccinations occurring at retail pharmacies, highlighting common chronic conditions among recipients. Additionally, there has been a decline in diagnosed COVID-19 patients and related treatments in recent months as vaccination efforts continue.
COVID-19 Trend Insights - Compiled on 6/11/2021
- 1. COVID-19 Weekly Trend Insights Compiled on 6/11/2021
- 2. • Global cases reached 174.5 million cases, which represents an increase of 6% from the last report. • Over 3.7 million deaths have occurred worldwide since the start of the pandemic. • South American countries have seena significant increase in cases, as Argentina and Uruguay lead the surge. Last report had data through week ending 5/28/2021 Confidential 2 Sources: https://www.nytimes.com/interactive/2021/world/covid-cases.html https://coronavirus.jhu.edu/map.html Confirmed Cases Worldwide COVID-19 INSIGHTS Confirmed Cases 174,570,342 Deaths 3,764,494 Total Vaccinations ~2,240,748,480
- 3. Confirmed Cases in the USA Confidential 3 COVID-19 INSIGHTS • The rate of U.S. cases continues to level off, as we observed an increase of 317K cases (approximately 1%) since our last report. • North Carolina garnered an increase in deaths of 2.3% since our last report, the highest among the top 10 states. Last report had data through week ending 5/28/2021 Confirmed Cases 33,420,582 Deaths 598,355 Sources: https://www.nytimes.com/interactive/2021/world/covid-cases.html https://coronavirus.jhu.edu/map.html State/Territory Confirmed Cases Case % Change Deaths Death % Change California 3,799,010 0.6% 63,611 1.1% Texas 2,971,646 1.1% 51,986 1.5% Florida 2,329,859 0.9% 36,972 1.4% New York 2,105,507 0.5% 52,914 -0.4% Illinois 1,390,331 1.2% 25,413 1.7% Pennsylvania 1,211,487 1.3% 27,472 1.8% Ohio 1,105,720 0.8% 20,021 1.6% Georgia 1,102,755 -1.5% 20,381 -1.4% New Jersey 1,018,491 0.5% 26,309 0.9% North Carolina 1,007,567 1.2% 13,252 2.3%
- 4. Confidential 4 Data Week 1 Current Year: June 12th, 2020 Data Week 52 Current Year: June 4th, 2021 Projected Retail, Unprojected Mail Order, Projected LTC, All Other TRx Counts NATIONAL TRENDS: Prescription activity continues to exceed 2020 pandemic trends overall, dropping only as a consequence of the Memorial Day holiday with week ending 6/4/2021. 3-Year National Trends (TRx) Rolling 12 Weeks: TRx % CHANGE COMPARED TO PRIOR YEARS Peak Pandemic Response March 20th, 2020
- 5. COVID-19 Vaccine Administration: Patient Demographic & Care Patterns 5 COVID-19 Special Report
- 6. Confidential 6 PFIZER 21 DAYS MODERNA 28 DAYS Covid-19 Vaccine Administration - Patient Demographics PRA observed a sample of 43.79 M patients vaccinated from Nov 5, 2020, to June 4, 2021. This patient group serves as a baseline to understand the demographics of patients receiving the Covid-19 Vaccine. 88% of the vaccine administrations in the sample have been distributed at a retail pharmacy. PRA US patient longitudinally linked medical and hospital claims data, raw patient volumes MEDIAN DAYS BETWEEN DOSES UNIQUE PATIENTS VACCINATED PERCENT OF DISTRIBUTION PATIENTS THAT HAVE RECEIVED THE COMPLETE COURSE OF VACCINATION PFIZER 24,121,952 55% 71.8% MODERNA 16,495,669 38% 73.5% JANSSEN 3,176,519 7% CAVEAT - While extensive in capture of clinical activity of US patients, PRA’s database may not include some activity of patients, if their claims were not submitted or captured in PRA’s data sources, accounting for difference in aggregated patient activity in comparison with public sources.
- 7. Confidential Covid-19 Vaccine Administration - Patient Ages by Week The average age of patients who have received the Covid-19 vaccine has been decreasing, with an increased in patients age group 10-19 7 PRA US patient longitudinally linked medical and hospital claims data, raw patient volumes
- 8. PRA leveraged insights from Chronic Conditions Present in Covid-19 Vaccinated Patients CAVEAT - This analysis is based on insights from our US Patient Real World Data to assess underlying conditions for patients that were administered the Covid-19 vaccine. Only the patients seen in medical claims with at least 2 visits during the 18-month lookback period were eligible for evaluation. For the risk factor/chronic condition to be included, patients were required to have at least 2 visits for the diagnosis in the 18-month look back period. PRA observed 19.2 M vaccinated patients eligible for analysis from Nov 5, 2020, to June 4, 2021. Confidential • 5.1 million vaccinated patients had at least 1 chronic condition. • The most common chronic conditions were T2DM, Obesity, and Heart Disease • Obesity was the most common in younger patients • 22% of patients had a history of hypertension diagnosis • 4% of patients had a history of Covid-19 diagnosis, prior to their first vaccine administration PRA US patient longitudinally linked medical and hospital claims data, raw patient volumes
- 9. COVID-19 Patient Monitoring: Demographics & Treatments Confidential 9 COVID-19: Overview of PRA Real World Data
- 10. Through patient activity observed for diagnosis, testing, exposure or symptoms of Covid-19 infection, PRA is tracking over 52M patients overall and over 6.5M diagnosed patients in its US real world data during the time period from Feb 2, 2020, to June 2, 2021 Patients could report in multiple status categories based on claims captured and mapped to status PRA US patient longitudinally linked medical and hospital claims data, raw patient volumes PRA US Patient Real World Data COVID-19 Infection Trends
- 11. PRA is tracking 197,817 Covid-19 patients during the most recent 4-week time period of May 9, 2021- June 5, 2021 Among the Covid-19 diagnosed patients: − Median age is 53 − 13% of the diagnosed patients had at least one record of inpatient care for their diagnosis. PRA US patient longitudinally linked medical and hospital claims data, raw patient volumes PRA US Patient Real World Data COVID-19 Diagnosed Patient Demographics *Patients could be covered by more than one payer type
- 12. Confidential Covid-19 Weekly Trends- Inceptive Place of Care for Diagnosed Patients There has been a decline in Covid-19 diagnosed patients, especially at Skilled Nursing Facilities since the Covid-19 vaccine rollout 12 PRA US patient longitudinally linked medical and hospital claims data, raw patient volumes RECENT 4- WEEK AVERAGE HOSPITAL INPATIENT 13% HOSPITAL- ER 7% OUTPATIENT 26% OFFICE 23% TELEHEALTH 7% SKILLED NURSING 0% URGENT CARE FACILITY 13% OTHER 10%
- 13. Confidential 13 Covid-19 Patients’ Acute Diagnosis by Week PRA US patient longitudinally linked medical and hospital claims data, raw patient volumes In the last 6 months, there has been a decline in respiratory failure, acute renal failure, sepsis, and hypoxemia
- 14. Confidential 14 Covid-19 Patients’ Symptoms by Week In the last 6-months, symptom distribution have been relatively steady with the most common symptoms being cough, muscle and body aches, and shortness of breath PRA US patient longitudinally linked medical and hospital claims data, raw patient volumes
- 15. 15 Confidential Treatments within 30 Days of COVID-19 Diagnosis PRA US patient longitudinally linked medical and hospital claims data, raw patient volumes 39% 58% 48% 44% 42% 38% 32% 27% 19% 40% 27% 35% 38% 39% 39% 38% 36% 32% 3% 10% 18% 17% 18% 15% 14% 11% 9% 1% 2% 8% 10% 11% 14% 16% 19% 22% 2% 2% 3% 4% 4% 5% 4% 3% <=9 10-19 20-29 30-39 40-49 50-59 60-69 70-79 80+ AZITHROMYCIN (38%) DEXAMETHASONE (38%) METHYLPREDNISOLONE (15%) REMDESIVIR (14%) BAMLANIVIMAB/ETESEVIMAB (4%) Possible Treatments within 30 days of Covid-19 Diagnosis (all ages, N=25,313) Possible Treatments by Age within 30 days of Covid-19 Diagnosis (N= 25,313) PRA evaluated 25,313 Covid-19 diagnosed patients for observed use of possible treatments within a 30- day window of Covid-19 diagnosis over the most recent 4- week period of May 9,2021 to June 5, 2021 Azithromycin and dexamethasone continue to be most common treatments